Promising results derived from a pilot trial of the MD Anderson Cancer Center (NCT03499353), in which gBRCA1/2m, HER2-negative, stage I-III BC patients, received neoadjuvant Talazoparib as single-agent during 4 to 6 months, without any chemotherapy, in order to evaluate the pathological complete response (pCR) rate and tolerance. This evidence concerns the gene ERBB2 and breast cancer.